Lenz Robert A. 4

What Happened Robert A. Lenz, a director of LB Pharmaceuticals, was granted a derivative award for 12,500 shares on June 3, 2026. The filing reports an acquisition at $0.00 (no cash paid). The award includes an option component (see footnotes) and was reported on an SEC Form 4 filed June 5, 2026.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely filing).
• Transaction type: Grant / award (derivative), 12,500 shares acquired at $0.00.
• Footnote F1: 2,500 of the shares are an option award under the issuer’s non-employee director compensation policy (prorated annual grant).
• Footnote F2: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting, subject to continuous service through vesting.
• Shares owned after the transaction: not disclosed in the filing.

Context This was an award of derivative securities rather than an open-market purchase or sale. The option portion has a time-based vesting condition; no immediate sale or cashless exercise is indicated. Awards to non-employee directors are a routine part of compensation and do not, by themselves, indicate a buying or selling signal.